• 5 min read
• Published on 11 July 2025
Listen to article
6:09Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article
Why Biotech's Patent Squabbles Could Be an Investor's Goldmine
Let’s be honest, watching two pharmaceutical behemoths like Pfizer and Moderna have a legal scrap over vaccine technology is rather entertaining. It’s a bit like a high-stakes soap opera, but with lab coats and billions of dollars instead of dramatic stares. To me, however, this isn't just corporate theatre. It’s a glaring signpost pointing to one of the most compelling investment themes of our time. The real prize isn't just who gets paid for past jabs, it's who controls the keys to the medical kingdom for the next twenty years.
I think people often misunderstand what they’re investing in with these companies. You’re not just buying a share in a factory that makes a specific pill. You’re buying a piece of an intellectual fortress. A strong patent is a government-granted monopoly, a legal wall that can keep competitors at bay for decades. It’s a beautiful, brutal, and fantastically profitable concept.
Take Moderna or BioNTech. Their entire business models are built on a foundation of mRNA technology patents. These patents are less like blueprints for a single product and more like a patent on the very concept of a brick. Anyone wanting to build a certain type of house in the future might have to pay you a fee. This is the very definition of a competitive advantage, what we at Nemo call the Biotech's IP Moat. It’s a powerful position that could generate licensing revenues from applications we haven’t even dreamed of yet, from cancer therapies to personalised medicines.
While the mRNA spat grabs the headlines, the real intellectual gold rush, in my opinion, is happening in gene editing. A company like CRISPR Therapeutics holds foundational patents on technology that could, quite literally, rewrite our DNA to cure genetic diseases. The value isn't in a single treatment. It's in the platform itself. They’ve effectively set up a tollbooth on the highway to genetic medicine.
This is where it gets interesting for investors. According to research from Nemo, companies with these platform technologies often present a different kind of opportunity. Their success isn't necessarily tied to a single drug trial. Even if one application fails, the underlying patent can still be immensely valuable, licensed out to other firms for their own projects. It’s a clever way to have multiple shots on goal.
Of course, the traditional challenge has been access. Shares in these pioneering companies don't exactly come cheap, making it difficult for the average person in the UAE or wider MENA region to build a properly diversified portfolio without a king's ransom. Frankly, it was a club with a high price of admission.
This is where the game has changed. Platforms like Nemo, which is regulated by the ADGM FSRA and partners with trusted institutions like DriveWealth and Exinity, allow for fractional share investing. You can now get exposure to these biotech investment opportunities with as little as a few dirhams. It means you can build a small, diversified basket of these IP-rich companies, rather than betting the farm on a single one. Nemo’s platform, which operates on a transparent spread model rather than commissions, also provides AI-powered analysis to help investors sift through the noise. For more detailed company information, you can always check the Nemo landing page.
This isn't about trying to time the market or pick the one winner from the patent wars. It's about using modern tools to gain exposure to a powerful, long-term trend. Still, one must be pragmatic. Investing in this sector is not for the faint of heart. Patent litigation is wildly unpredictable, and a single court ruling could send a stock tumbling. All investments carry risk and you may lose money. This is an observation, not a recommendation. But for those with a bit of patience and a stomach for volatility, the companies building these intellectual property fortresses could be the ones that define the future of medicine and wealth creation.
View the full Basket:Biotech's IP Moat
View the full Basket:Biotech's IP Moat
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 12 September 2026
Read article
Published on 11 September 2026
Read article
Published on 11 September 2026
Read article